Author: pr-moritz
Last saved by: Roland Birkhoff
Company: Bayer
Document comments: V-2025-03-04

PCB litigation: Washington Supreme Court ruling in Erickson
•	Company has appeals pending in eight prior verdicts, each of which have their own separate issues that were not before the Erickson Court
•	Company is considering options for further legal review of the decision 
•	Company previously announced agreements in principle to resolve all SVEC cases, except Erickson and eight other verdicts which remain on appeal

Leverkusen, October 30, 2025 – The Washington Supreme Court today issued a decision in Erickson vs. Monsanto which impacts several legal issues across cases involving allegations of exposure to polychlorinated biphenyls (PCBs) at the Sky Valley Education Center (SVEC). 

The company disagrees with the Supreme Court’s decision to reverse the Court of Appeals in Erickson and deny Monsanto’s cross-petition regarding the availability of punitive damages. In particular, the company believes that the Court’s choice-of-law analyses underlying its rulings on punitive damages and the statute of repose are wrong and contrary to the U.S. Constitution because the rulings unlawfully discriminate against out of state companies doing business in Washington. Three dissenting justices found in favor of the company on its entitlement to a statue of repose defense under Washington law, writing: ‘…courts are not supposed to start their analysis with policy preferences when there’s a state statute right on point.’ The company is considering its legal options.

Erickson was the first case involving allegations of PCB exposure at SVEC to go to trial in 2021. On appeal, the intermediate appellate court vacated the judgment and reversed the trial court on three cross-cutting issues in the litigation. Plaintiffs then filed an appeal with the state Supreme Court and Monsanto cross-petitioned on punitive damages, arguing that Washington’s Product Liability Law under which this and subsequent cases were tried does not permit them.

The company has appeals or post-trial motions pending in eight other SVEC cases. These actions raise additional questions of law beyond those at issue in Erickson and will move forward through the appellate process. Each case is unique and has its own factual and legal record. Examples of the range of issues raised in these other cases include the application of Missouri’s offset statute for punitive damages—which generally prohibits punishing a defendant more than once for the same conduct—along with due-process limits on punitive damages; the trial courts’ exclusion of evidence of alternative causes and pre-existing conditions for the injuries at issue; and the courts’ refusal to instruct the jury on superseding cause. 

In August, the company announced it had reached agreements in principle to resolve all SVEC cases, except Erickson and eight other prior adverse verdicts which remain on appeal. The terms of the agreements in principle are confidential. The company is confident in its legal strategy and prepared to defend itself at trial but will consider resolving cases when it is strategically advantageous to do so.

Monsanto also has a case pending in Missouri to enforce its indemnity agreements with former purchasers of PCBs who manufactured electrical equipment in order to recover legal costs, settlements and judgments.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contact for media inquiries:
Brian Leake, phone +1 314 370 3285
Email: brian.leake@bayer.com

Philipp Blank, phone +49 214 30-20499
Email: philipp.blank@bayer.com

Contact for investor inquiries:
Bayer Investor Relations Team, phone +49 214 30-72704
Email: ir@bayer.com 
www.bayer.com/en/investors/ir-team

Find more information at www.bayer.com.

pb	(2025-0206E)

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.